Galena Biopharma, Inc. — FY2011 Form 10-K
Entity and period: The filing is for Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), for the fiscal year ended December 31, 2011. It is not a SELLAS Life Sciences Group filing. Galena changed its name in September 2011 and acquired Apthera, including NeuVax, in April 2011; therefore, 2011 results reflect a major change in business focus and do not represent a full year of Apthera operations.
Business context and pipeline
Galena was a development-stage biotechnology company focused on peptide-based cancer immunotherapies. Its lead candidate, NeuVax (E75), targets recurrence prevention in a subset of early-stage, low-to-intermediate HER2-positive breast cancer patients. The Phase 3 PRESENT trial began enrollment in January 2012 and was planned for approximately 700 patients; the FDA had concurred with the study design under a Special Protocol Assessment. Galena also acquired Folate Binding Protein (FBP), for which it announced a Phase 1/2 ovarian and endometrial cancer trial in February 2012.
Galena contributed substantially all RNAi assets to subsidiary RXi in September 2011 and was pursuing a conditional partial spin-off. The proposed distribution and associated RXi financing were not assured at the filing date.
Financial results and liquidity
| Metric | FY2011 / Dec. 31, 2011 | FY2010 / Dec. 31, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $11.538 million | $7.873 million |
| General and administrative expense | $9.249 million | $8.752 million |
| Operating loss | $20.787 million | $16.625 million |
| Net loss | $11.485 million | $11.993 million |
| Basic and diluted loss per share | $0.32 | $0.67 |
| Net cash used in operating activities | $14.668 million | $10.257 million |
| Cash and cash equivalents | $11.433 million | $6.891 million |
2011 net loss included $9.302 million of net other income, substantially affected by noncash changes in the fair value of warrants. Thus, the lower reported net loss versus 2010 did not reflect improved operating performance. R&D expense rose 47%, primarily from NeuVax Phase 3 preparation. Profit margins are not meaningful because the company had no revenue.
At year-end, total assets were $30.968 million, total liabilities $20.856 million, and stockholders’ equity $10.112 million. Current assets were $11.810 million and current liabilities $11.202 million. Current liabilities included $500,000 of convertible notes, $3.746 million of warrants potentially settleable in cash, and $1.782 million of current contingent acquisition consideration. Capital lease obligations totaled approximately $67,000. Cash was approximately $8.2 million on March 26, 2012. The company said cash and proceeds available under its February 2012 at-the-market equity sales agreement, which permits up to $10 million in sales, should fund operations through at least Q1 2013; this is management’s estimate, not a guarantee.
Changes, outlook, risks, and unusual items
- Period comparison: Operating loss widened by approximately $4.2 million; operating cash use increased by approximately $4.4 million. Net loss narrowed by approximately $0.5 million mainly due to higher noncash warrant-related income. Share count increased substantially following equity offerings, the Apthera acquisition, and other stock issuances.
- Acquisition and commitments: Apthera consideration included approximately 5.0 million shares and contingent payments of up to $32 million tied to NeuVax milestones. The first $1 million milestone was triggered when the Phase 3 trial enrolled its first patient; 1,315,789 restricted shares were issued into escrow in March 2012, subject to stockholder approval. The Phase 3 trial was expected to cost more than $50 million to reach its primary endpoint.
- Funding outlook: Galena expected significant losses and higher R&D costs as NeuVax and FBP trials advanced, and stated it might never become profitable. Additional capital may be required; equity issuance could dilute shareholders. The RXi financing included a bridge loan guaranteed by Galena and secured in part by Galena’s RXi shares, creating potential repayment exposure if the transaction did not close.
- RXi separation uncertainty: The proposed one-for-one RXi share distribution was conditional on financing and other requirements, including trading arrangements and a deadline associated with RXi’s registration statement. The investors or Galena could terminate the agreement under specified circumstances; the filing provides no assurance the distribution would be completed.
- Litigation: Warrant holders sued over alleged rights to require warrant repurchases, initially claiming approximately $5.2 million in aggregate. Most demands were withdrawn in March 2012; Galena tendered $355,000 for the remaining 500,000 underlying shares. The plaintiffs reserved rights, and Galena considered most claims moot, so the matter was not fully resolved in the filing.
- Other principal risks: NeuVax and FBP remain investigational; trial outcomes, enrollment, regulatory approval, manufacturing supply, reimbursement, competition, intellectual-property protection, and financing are uncertain. Management disclosed a material weakness identified in 2011 related to accounting for certain modified options and potentially cash-settleable warrants; it described additional review procedures and concluded controls were effective at year-end. The financial statement audit was unqualified, but the auditor did not provide an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether the RXi financing and conditional share distribution closed, and the resulting ownership, guarantee, and cash obligations.
- Actual spending, enrollment, and clinical milestones for PRESENT and FBP, versus management’s funding runway and Phase 3 cost estimates.
- Subsequent cash balance and shares sold under the $10 million at-the-market agreement, including dilution and remaining capacity.
- Final status and potential remaining exposure from the warrant-holder litigation and the Apthera milestone shares and contingent consideration.
- Whether the disclosed control remediation remained effective and whether later filings reported further accounting or control issues.